Andros Pharmaceuticals Andros Pharmaceuticals (竟天生物科技股) is a biopharmaceutical company engaged in developing drug delivery platform technologies. | Locate Bio Locate Bio (formerly RegenTec) is a specialist regenerative medicine company developing cell and gene therapy programmes. | Haplogen Haplogen is a biopharmaceutical company that focuses on therapeutic programs in the area of virus-caused diseases. | ![]() Asklepios BioPharmaceutical Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein. | ![]() Regenxbio Regenxbio is a clinical-stage biotechnology company providing gene therapy product candidates for the treatment of retinal, metabolic, and neurodegenerative diseases. | |
Founding Date | Founding Date 2008 | Founding Date 2001 | Founding Date 2010 | Founding Date 2001 | Founding Date 2009 |
Type | Type Private | Type Private | Type Subsidiary | Type Private | Type Public |
Tags | |||||
Locations | Locations TW HQ | Locations Nottingham, GB HQ | Locations Wien, AT HQ | Locations Chapel Hill, US HQ Roslin, GB | Locations Rockville, US HQ |
Employees | Employees 5 | Employees 254% decrease | Employees 2 | Employees 5172% increase | Employees 4018% increase |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 11.5m (about 2 years ago) | Latest funding round N/A | Latest funding round $ 235m (about 7 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised N/A | Total funding raised $ 8.5m | Total funding raised N/A | Total funding raised $ 235m | Total funding raised $ 118.9m |
Locate Bio (formerly RegenTec) is a specialist regenerative medicine company developing cell and gene therapy programmes.
View companyHaplogen is a biopharmaceutical company that focuses on therapeutic programs in the area of virus-caused diseases.
View company
Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein.
View company
Regenxbio is a clinical-stage biotechnology company providing gene therapy product candidates for the treatment of retinal, metabolic, and neurodegenerative diseases.
View company